BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14737055)

  • 21. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
    Yakushijin Y; Shikata H; Takaoka I; Horikawa T; Takeuchi K; Yamanouchi J; Azuma T; Narumi H; Hato T; Yasukawa M
    Int J Clin Oncol; 2011 Apr; 16(2):118-24. PubMed ID: 20924633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
    Rondinelli PI; Ribeiro Kde C; de Camargo B
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):665-70. PubMed ID: 17023827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases.
    Kavgaci H; Ozdemir F; Aydin F; Yavuz A; Yavuz M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):475-9. PubMed ID: 12636092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GM-CSF in chemotherapy-induced febrile neutropenia--a double-blind randomized study.
    Arnberg H; Letocha H; Nõu F; Westlin JF; Nilsson S
    Anticancer Res; 1998; 18(2B):1255-60. PubMed ID: 9615797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
    Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
    J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytokines in cancer chemotherapy: present state and problems in use of G- and GM-CSF for solid tumors in Japan].
    Ogawara M
    Gan To Kagaku Ryoho; 1998 Jan; 25(2):164-70. PubMed ID: 9474924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed Granulocyte Colony-Stimulating Factor (G-CSF) Administration after Chemotherapy Reduces Total G-CSF Doses without Affecting Neutrophil Recovery in a Randomized Clinical Study in Children with Solid Tumors.
    Yankelevich M; Hoogstra DJ; Abrams J; Chu R; Bhambhani K; Taub JW
    Pediatr Hematol Oncol; 2020 Nov; 37(8):665-675. PubMed ID: 32643500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
    Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo.
    Bönig HB; Hannen M; Lex C; Wölfel S; Banning U; Nürnberger W; Körholz D; Göbel U
    Cancer; 1999 Jul; 86(2):340-8. PubMed ID: 10421271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G-CSF during large field radiotherapy reduces bone marrow recovery capacity.
    Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E
    Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: use of a new 3-day-a-week regimen.
    Jayabose S; Tugal O; Sandoval C; Li K
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):338-40. PubMed ID: 7526722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
    Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
    Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
    Shochat E; Rom-Kedar V
    Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
    Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
    Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical model for G-CSF administration after chemotherapy.
    Foley C; Mackey MC
    J Theor Biol; 2009 Mar; 257(1):27-44. PubMed ID: 19007795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.